 Mereo BioPharma Group plc NASDAQ: MREO has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat MPH-966 in severe alpha-1 antitrypsin deficiency-AATD associated emphysema. Emphysema is a lung disease caused by damage to the small air sacs in. 